Executives from Billy and Alza are heading the lead. Its sales are falling, but its shares are rising.
The pill is undergoing an important transformation. The new CEO, Petr Toupal (with a wealth of experience from Billy), takes over the leadership after Peter Klekner, who was brought into the company by Tomáš Čupr. The new members of the top team are Aleš Velín from Alza as CFO and Jiří Caudr, who was entrusted with the marketing strategy.
In the first half of 2025, the company significantly reduced central administration costs — by almost half year-on-year, sold part of its brick-and-mortar pharmacies and reduced debt with the main bank by 40%. Sales for the first seven months reached CZK 575 million, representing more than 30% drop Compared to last year, but The company's shares rose by more than 70% year-on-year.
This change isn't just about new names -- the Pill is transforming toward digital prevention and longevity services, restructuring itself to be leaner, more efficient and better prepared for growth.
👉 More about these key changes and how the Pill is heading into the future can be found at CzechCrunch
